PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.
about
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients.More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosisThe truncated splice variant of peroxisome proliferator-activated receptor alpha, PPARα-tr, autonomously regulates proliferative and pro-inflammatory genesDonor PPARα Gene Polymorphisms Influence the Susceptibility to Glucose and Lipid Disorders in Liver Transplant Recipients: A Strobe-Compliant Observational StudyInterstrain differences in the severity of liver injury induced by a choline- and folate-deficient diet in mice are associated with dysregulation of genes involved in lipid metabolism.Molecular Interactions between NAFLD and Xenobiotic Metabolism.A multi-scale modeling framework for individualized, spatiotemporal prediction of drug effects and toxicological risk.Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" ProblemRole of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny.Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel responseMembrane Associated Progesterone Receptors: Promiscuous Proteins with Pleiotropic Functions - Focus on Interactions with Cytochromes P450.Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications.CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy.Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.Genes and beans: pharmacogenomics of renal transplant.Lipid-lowing pharmacogenomics in Chinese patients.The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.Advantages of cell-based high-volume screening assays to assess nuclear receptor activation during drug discovery.Functional gene variants of CYP3A4.Pharmacogenomics of acetaminophen in pediatric populations: a moving target.Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients.Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.Enhanced Metabolizing Activity of Human ES Cell-Derived Hepatocytes Using a 3D Culture System with Repeated Exposures to Xenobiotics.Pharmacogenomics in epilepsy.Pharmacogenetics of posttransplant diabetes mellitus.CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomesPeroxisome proliferator-activated receptor alpha, PPARα, directly regulates transcription of cytochrome P450 CYP2C8.Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation.Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia.Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach.Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.Expression of CYP3A4 and CYP3A7 in Human Foetal Tissues and its Correlation with Nuclear Receptors.Dynamics of Cytosine Methylation in the Proximal Promoters of CYP3A4 and CYP3A7 in Pediatric and Prenatal Livers.Effect of polymorphisms in CYP3A4, PPARA, NR1I2, NFKB1, ABCG2 and SLCO1B1 on the pharmacokinetics of lovastatin in healthy Chinese volunteers.
P2860
Q33628473-9D6ED8E1-516D-4079-AE15-1C7E500E412CQ33665154-8A89201A-B621-4DBE-B446-46AD98C0388DQ34023028-9EC1B0FE-C0B7-44BF-A154-ADE6E1D39B18Q34994708-D2AD7DE3-A18A-44CE-9015-081778E5E13FQ35677612-12C5445E-AC5C-4B1F-A41E-4ACACF757022Q36194349-2B0D4F5D-67DF-4511-B713-304A65465F8FQ36329819-5899F1AF-83CB-4888-939C-2EBBC5873AF5Q36549795-944C9448-1D84-4DAE-B755-81EAB399C75CQ36550939-47546F64-13EA-47D0-A54A-F682ADC18F6AQ36634077-9DE8BC40-D513-4AAD-A92E-4E8EE61215C0Q37062637-276CDD30-11AF-462D-90E1-F3C526C21140Q37390889-726712B1-C062-4A12-BBCA-D728D9F75F5FQ37721257-CAC90877-672F-4E61-9937-22200441297BQ38063426-4FC5D04E-EF56-4780-AFD3-0763B6FAE7C7Q38068539-369F3C13-96DF-4007-B2DB-C7DC5F0A12EBQ38086777-73FBFC56-104D-4424-B704-5336C4A64DCFQ38103593-ED5CB71E-8412-4BF9-9CD3-40B44F9F8FDAQ38104742-7007CA36-688D-454E-BB04-AAD960D01F35Q38129422-41284171-114C-425E-81BE-19999DBA7FA4Q38163945-76475E58-B4DA-4072-9C00-828ACBE61F4BQ38211210-1BB14B11-A841-4615-B4E9-FE75A35361F9Q38220008-E692D917-6C18-4140-9384-A026FE755F69Q38263519-8162CFC6-D85B-423B-9970-59CCD7284A14Q38435024-B4FE3738-D483-4D0C-9316-E7A420D1F8D9Q38787174-96CE843F-C505-42C4-BF9A-2524C3E56388Q38821274-C4F8D0FF-197B-4FF0-97B7-683ADB26CF38Q38862327-416E2961-8EF7-4FA2-B77D-F876CB6826DCQ39084353-35698D1A-F0BE-407A-AC2A-0E8FBF158460Q39204562-9850E803-F7E9-4B88-9B3E-E7BB1116A819Q39534657-8339317D-CFC2-412F-81E3-36933FAE4BEBQ40305168-A0684850-C709-46AB-9082-3D1823904DB9Q40780592-44EFE454-E3BC-425C-82E6-AD9EB1DF9755Q41328717-1A665817-9F36-469D-8E25-AA2294D84D05Q42215557-C4C5D77E-7063-4151-B7AB-1141E44483F2Q43826505-51BF93EE-F836-4960-85C7-AB05187E8AE3Q43965937-00397003-E8BF-4E1B-B973-7EC96D4FEB46Q47820302-CFE8FEDD-201B-4BCB-8BAF-DEFC184CBA5AQ50048008-C46A27AE-0090-4B2C-8CA7-C26F53FBDF27Q50540290-BC1EA90D-1573-4709-9A7B-1776D2E93B32Q51266635-8507A2F1-7249-43B8-B27F-A48D259EA483
P2860
PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.
@en
PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.
@nl
type
label
PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.
@en
PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.
@nl
prefLabel
PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.
@en
PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.
@nl
P2093
P50
P356
P1476
PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.
@en
P2093
Andreas K Nussler
Kathrin Klein
Matthias Schwab
Stefan Winter
P304
P356
10.1038/CLPT.2011.336
P407
P577
2012-06-01T00:00:00Z